AstraZeneca

# news release

2003-10-30

**ASTRAZENECA RECEIVES FDA APPROVABLE LETTER FOR SEROQUEL™ (QUETIAPINE FUMARATE) TABLETS IN TREATMENT OF MANIA**

AstraZeneca today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its Supplemental New Drug Applications (sNDAs) for the use of SEROQUEL as both an adjunct and monotherapy for the treatment of manic episodes associated with bipolar disorder. The company is working closely with the FDA to supply information and to finalize labelling.

**Media Enquiries:**
Chris Major, +44 (0) 207 304 5028

**Investor Enquiries:**
Mina Blair-Robinson, +44 (0) 207 304 5084
Jonathan Hunt, +44 (0) 207 304 5087